Diamyd says retogatein delays progression to insulin-dependent type 1 diabetes by more than five years in DiAPREV-IT follow-up study

• Diamyd Medical reported long-term follow-up from the randomized, placebo-controlled DiAPREV-IT trial; results will be published in Diabetologia.
• Retogatein delayed progression to insulin-dependent type 1 diabetes for more than five years in a genetically defined subgroup of children.
• The effect was concentrated in children with GAD antibodies, additional islet autoantibodies, and the HLA DR3-DQ2 profile.
• The readout supports retogatein’s positioning as a targeted, disease-modifying immunotherapy in early-stage type 1 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diamyd Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 202609240920BITN____UKPR__SV_20260924-BIT-4969-0) on September 24, 2026, and is solely responsible for the information contained therein.